ST266

About Noveome Biotherapeutics

Noveome Biotherapeutics is a private, clinical-stage company developing ST266, a proprietary secretome-derived biologic. Its platform leverages a complex mixture of hundreds of proteins and factors designed to mimic and stimulate the body's natural healing processes across multiple pathways. The pipeline includes programs in necrotizing enterocolitis (NEC) in premature infants and various ophthalmic indications, with early clinical trials demonstrating promising tolerability and biologic activity. Led by a team with deep pharmaceutical experience, particularly from Allergan, Noveome is positioning its multi-targeted approach as a potential solution for complex, inflammatory, and tissue-damaging diseases with high unmet need.

About Noveome Biotherapeutics

Noveome Biotherapeutics is a private, clinical-stage company developing ST266, a proprietary secretome-derived biologic. Its platform leverages a complex mixture of hundreds of proteins and factors designed to mimic and stimulate the body's natural healing processes across multiple pathways. The pipeline includes programs in necrotizing enterocolitis (NEC) in premature infants and various ophthalmic indications, with early clinical trials demonstrating promising tolerability and biologic activity. Led by a team with deep pharmaceutical experience, particularly from Allergan, Noveome is positioning its multi-targeted approach as a potential solution for complex, inflammatory, and tissue-damaging diseases with high unmet need.

Therapeutic Areas